In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Alcon (ALC – Research Report), with a price target of $105.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Larry Biegelsen’s rating is based on several factors that suggest a positive outlook for Alcon despite recent challenges. Although the loss of exclusivity for Simbrinza is expected to pose a modest headwind to Alcon’s sales growth and earnings per share, Biegelsen anticipates that the company will continue to see medium single-digit sales growth and margin expansion driven by new product launches.
Moreover, the recent patent ruling, while allowing for potential generic competition, is not expected to significantly impact Alcon’s financial performance in the near term. The company’s ability to appeal the decision and the likelihood that generic manufacturers will face their own patent litigations are seen as mitigating factors. Additionally, Biegelsen’s confidence is bolstered by the belief that the judge’s sound and comprehensive rulings make them less likely to be overturned on appeal, thereby providing a certain level of protection for Alcon’s patents in the interim.